Last reviewed · How we verify

Open-label Ikervis — Competitive Intelligence Brief

Open-label Ikervis (Open-label Ikervis) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Immunosuppressant (topical ophthalmic). Area: Ophthalmology.

phase 3 Immunosuppressant (topical ophthalmic) Calcineurin (via cyclosporine binding to cyclophilin) Ophthalmology Small molecule Live · refreshed every 30 min

Target snapshot

Open-label Ikervis (Open-label Ikervis) — Santen SAS. Ikervis is a lipid emulsion eye drop that reduces inflammation and promotes tear production in dry eye disease by delivering cyclosporine to the ocular surface.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Open-label Ikervis TARGET Open-label Ikervis Santen SAS phase 3 Immunosuppressant (topical ophthalmic) Calcineurin (via cyclosporine binding to cyclophilin)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Immunosuppressant (topical ophthalmic) class)

  1. Santen SAS · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Open-label Ikervis — Competitive Intelligence Brief. https://druglandscape.com/ci/open-label-ikervis. Accessed 2026-05-15.

Build your own brief

Pick any drug + add comparators: